Commissions do not affect our editors' opinions or evaluations. With unlimited 2% cash back on purchases, the Capital One Spark Cash Plus (rates & fees) is an excellent business cash-back card for ...

Biogen has added a preclinical-stage drug candidate for Parkinson's disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Healthcare analytics company PurpleLab joined the Network Advertising Initiative. Biogen and Neomorph announced a multi-target research collaboration to discover and develop molecular glue degraders ...

The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, Bionews, and are intended to spark discussion about issues pertaining to multiple sclerosis.

Biogen Inc. (NASDAQ:BIIB) the central nervous system disease drug developer based in Cambridge Massachusetts, reported its Q3 earnings yesterday, Wednesday, October 30. First, let's look at some ...

Spark has made it clear it is getting back to basics and considering the sale of non-core assets, as the telecommunications company looks to put itself on track for growth. The company cut its full ...

Biogen Inc. ( (BIIB)) has realeased its Q3 earnings. Here is a breakdown of the information Biogen Inc. presented to its investors. Biogen Inc. is a leading biotechnology company that specializes ...

GitHub has unveiled GitHub Spark, a new AI tool set to transform the landscape of personalized application development. This innovative platform enables you to create, deploy, and share fully ...